Gastrointestinal side effects: GLP-1-based agents, including retatrutide, commonly cause nausea, vomiting, diarrhoea, and reduced appetite, partly through slowing of gastric emptying
Shereef Elnahal said roughly $2 billion of the $6.6 billion requested from Congress is needed for weight-loss drugs known as glucagon-like peptide 1, or GLP-1, agonists, and new medications for illnesses found in veterans, such as metabolic dysfunction-associated steatohepatitis, or MASH, a fatty liver disease
If a patient has any of these signs or is worried about possible side effects, they should talk to their healthcare provider as soon as possible
The needle should be long enough to reach the muscle without penetrating the nerves and blood vessels underneath
Reactive oxygen species in inflammation and tissue injury
Across a full dose-response curve from 11,000 ng/mL, this produces consistent misinterpretation of potency